All Videos

Haws offers advice to female clinicians about leadership, collaboration, and the future of the aesthetics industry.

Christophe Piketty, MD, PHD, discusses the promising efficacy, novel mechanisms, and patient benefits of nemolizumab in targeting IL-31 for atopic dermatitis and prurigo nodularis.

Well Revolution’s partnership with City Chemist highlights how telehealth can sustain small businesses and improve patient care.

Professor Diamant Thaçi, MD, PhD, discusses findings from the ARCADIA and OLYMPIA clinical trial programs, highlighting nemolizumab’s rapid efficacy in treating atopic dermatitis and prurigo nodularis.

This collective initiative gives Mindy Haws, MD, and her team the ability to reach more women in a way that gives back and helps them succeed.

Mindy Haws, MD, spoke to Dermatology Times about the new videos, podcasts, and other resources LIMITLESS offers for women at all stages of their careers.

Panelists discuss the topical treatment option roflumilast for pediatric atopic dermatitis, exploring its mechanism of action, efficacy, safety, and potential role in managing the condition.

The panelist discusses how systemic atopic dermatitis therapies now emphasize targeted biologics and Janus kinase inhibitors, requiring personalized approaches, comprehensive monitoring, and holistic patient management.

The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.

Panelists discuss the latest advances in topical treatments for pediatric atopic dermatitis, covering newly available options and those on the horizon with a focus on their mechanisms of action, efficacy, and safety profiles.

The panelist discusses how to evaluate and select appropriate therapeutic options for a 10-year-old girl while considering factors such as safety, efficacy, and treatment adherence.

The panelist discusses how understanding the diverse manifestations of atopic dermatitis enables health care providers to develop personalized treatment approaches for optimal patient outcomes.

The co-founder of PathAI and its PathAssist Derm tool believes AI is going to be incredibly valuable for dermatologists and dermatopathologists.

Merz Aesthetics' global study reveals that aesthetic treatments boost self-confidence, social well-being, and self-perception beyond physical appearance.

Although the tool is currently designed for research use only, CEO Andy Beck, MD, PhD, is excited about its future in clinical dermatopathology.

Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.

“I think some key things that stand out to me are that it's safe, effective, backed by rigorous clinical data, and has very high patient satisfaction,” Watchmaker said about the new product.

The overwhelmingly positive feedback from both clinicians and patients reinforces the unmet need roflumilast foam is addressing in seborrheic dermatitis care.

Jonathan Zalevsky, PhD, discusses the fundamentally different path of Rezpeg compared with existing IL-4 and IL-13 inhibitors in atopic dermatitis.

Michael Rubio, PA-C, and Renata Block, MMS, PA-C discuss the complexities associated with practicing telemedicine, especially as a PA.

The panelist discusses how a 35-year-old man with atopic dermatitis requires personalized, comprehensive management considering skin of color complexities, focusing on trigger identification, targeted therapies like dupilumab, and holistic approach to inflammation, skin barrier protection, and aesthetic concerns.

Panelists discuss the unique challenges of managing atopic dermatitis in children compared with adults, focusing on factors such as skin barrier differences, treatment adherence, and the impact on growth and development.

The panelist discusses how an 8-year-old girl with moderate to severe atopic dermatitis requires a comprehensive treatment approach focusing on dupilumab as a potential systemic therapy. Treatment goals include reducing inflammation, improving quality of life, and providing age-appropriate, empathetic care while addressing patient and caregiver concerns about efficacy and safety.

Panelists discuss the mental and physical burden of atopic dermatitis on pediatric patients and their caregivers and share approaches to addressing the psychosocial impact of the condition, highlighting how these factors influence treatment selection and care strategies.

Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.

Michael Rubio, PA-C talks with Renata Block, MMS, PA-C, about his virtual care platform and how it can expand access to care.

Renata Block, MMS, PA-C, and Michael Rubio, PA-C discuss the complexities of developing a telehealth program in the world of dermatology.

Catch up on coverage from the 2025 South Beach Symposium held in Miami Beach, Florida.

Panelists discuss how atopic dermatitis is linked to other type 2 inflammatory conditions in the pediatric population, exploring the shared immune pathways and comorbidities that connect these disorders.

Panelists discuss the pathophysiology of atopic dermatitis, highlighting the role of type 2 inflammation in driving the disease process and explaining how this inflammation contributes to the characteristic itch-scratch cycle seen in affected individuals.